STTK
Shattuck Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.37
−0.92%Year over year
Reported trailing growth
- Revenue
- -66.6%
- EBITDA
- +18.3%
- EBIT
- +14.2%
- EPS
- +57.9%
- Free cash flow
- +26.3%
- Operating cash flow
- +26.6%
Forward estimates
Based on analyst estimates
- Revenue
- -73.1%
- EBITDA
- -17.1%
- EPS
- +9.0%
Three-year CAGR
- Revenue
- +15.3%
- EBITDA
- +37.0%
- EBIT
- +36.1%
- Net income
- +35.3%
- EPS
- +53.0%
- Free cash flow
- +34.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026